DV
Dividend Vision

ODTX — Odyssey Therapeutics, Inc. Common Stock

Odyssey Therapeutics, Inc. Common Stock (ODTX)

Total return is 15.2% over the past 0.3 years, 8.8 points ahead of SPY at 6.4%.

Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing oral and protein-based medicines for autoimmune and inflammatory diseases, with a pipeline that includes candidates targeting ulcerative colitis, lupus, and other immune-mediated conditions. The company does not currently distribute to shareholders. As an early-stage biotech firm with no approved products, it appeals primarily to investors with high risk tolerance seeking exposure to clinical-stage drug development rather than current income.

ODTX key facts

Asset type
Stock
Asset class
Equity
Inception date
05/07/2026
Last close
$20.73
Market cap
$844,390,592
Average volume
136300.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.15